225 related articles for article (PubMed ID: 29055013)
1. A Synthetic CD8α:MyD88 Coreceptor Enhances CD8
Kaczanowska S; Joseph AM; Guo J; Tsai AK; Lasola JJ; Younger K; Zhang Y; Gonzales CV; Davila E
Cancer Res; 2017 Dec; 77(24):7049-7058. PubMed ID: 29055013
[TBL] [Abstract][Full Text] [Related]
2. Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens.
Geng D; Zheng L; Srivastava R; Velasco-Gonzalez C; Riker A; Markovic SN; Davila E
Cancer Res; 2010 Oct; 70(19):7442-54. PubMed ID: 20807806
[TBL] [Abstract][Full Text] [Related]
3. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
[TBL] [Abstract][Full Text] [Related]
4. TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8α+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface.
Crespo MI; Zacca ER; Núñez NG; Ranocchia RP; Maccioni M; Maletto BA; Pistoresi-Palencia MC; Morón G
J Immunol; 2013 Feb; 190(3):948-60. PubMed ID: 23284054
[TBL] [Abstract][Full Text] [Related]
5. Impaired cross-presentation of CD8α+ CD11c+ dendritic cells by Japanese encephalitis virus in a TLR2/MyD88 signal pathway-dependent manner.
Aleyas AG; Han YW; Patil AM; Kim SB; Kim K; Eo SK
Eur J Immunol; 2012 Oct; 42(10):2655-66. PubMed ID: 22706912
[TBL] [Abstract][Full Text] [Related]
6. Age-associated alterations in CD8α+ dendritic cells impair CD8 T-cell expansion in response to an intracellular bacterium.
Li G; Smithey MJ; Rudd BD; Nikolich-Žugich J
Aging Cell; 2012 Dec; 11(6):968-77. PubMed ID: 22862959
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88.
Bates JT; Graff AH; Phipps JP; Grayson JM; Mizel SB
J Immunol; 2011 Jun; 186(11):6255-62. PubMed ID: 21515787
[TBL] [Abstract][Full Text] [Related]
8. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway.
Wilson NS; Yang B; Morelli AB; Koernig S; Yang A; Loeser S; Airey D; Provan L; Hass P; Braley H; Couto S; Drane D; Boyle J; Belz GT; Ashkenazi A; Maraskovsky E
Immunol Cell Biol; 2012 May; 90(5):540-52. PubMed ID: 21894173
[TBL] [Abstract][Full Text] [Related]
9. Infectious Sporozoites of
Parmar R; Patel H; Yadav N; Parikh R; Patel K; Mohankrishnan A; Bhurani V; Joshi U; Dalai SK
Front Immunol; 2018; 9():192. PubMed ID: 29472929
[TBL] [Abstract][Full Text] [Related]
10. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
[TBL] [Abstract][Full Text] [Related]
11. A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population.
Wu CC; Liu SJ; Chen HW; Shen KY; Leng CH
Oncotarget; 2016 May; 7(21):30804-19. PubMed ID: 27127171
[TBL] [Abstract][Full Text] [Related]
12. Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens.
Farrand KJ; Dickgreber N; Stoitzner P; Ronchese F; Petersen TR; Hermans IF
J Immunol; 2009 Dec; 183(12):7732-42. PubMed ID: 19923446
[TBL] [Abstract][Full Text] [Related]
13. Myeloid differentiation factor 88 is required for cross-priming in vivo.
Palliser D; Ploegh H; Boes M
J Immunol; 2004 Mar; 172(6):3415-21. PubMed ID: 15004140
[TBL] [Abstract][Full Text] [Related]
14. Delivered antigen peptides to resident CD8α
Wang L; Wang Z; Qin Y; Liang W
Eur J Pharm Biopharm; 2020 Feb; 147():76-86. PubMed ID: 31887349
[TBL] [Abstract][Full Text] [Related]
15. Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects.
Joseph AM; Srivastava R; Zabaleta J; Davila E
Cancer Immunol Res; 2016 Aug; 4(8):708-16. PubMed ID: 27267778
[TBL] [Abstract][Full Text] [Related]
16. CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.
Ghorashian S; Veliça P; Chua I; McNicol AM; Carpenter B; Holler A; Nicholson E; Ahmadi M; Zech M; Xue SA; Uckert W; Morris E; Chakraverty R; Stauss HJ
J Immunol; 2015 Feb; 194(3):1080-9. PubMed ID: 25539815
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
18. Blockade of Myd88 signaling induces antitumor effects by skewing the immunosuppressive function of myeloid-derived suppressor cells.
Hong EH; Chang SY; Lee BR; Kim YS; Lee JM; Kang CY; Kweon MN; Ko HJ
Int J Cancer; 2013 Jun; 132(12):2839-48. PubMed ID: 23184679
[TBL] [Abstract][Full Text] [Related]
19. Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
Altvater B; Pscherer S; Landmeier S; Kailayangiri S; Savoldo B; Juergens H; Rossig C
Cancer Immunol Immunother; 2012 Mar; 61(3):385-96. PubMed ID: 21928126
[TBL] [Abstract][Full Text] [Related]
20. CD8alpha-11b+ dendritic cells but not CD8alpha+ dendritic cells mediate cross-tolerance toward intestinal antigens.
Chung Y; Chang JH; Kweon MN; Rennert PD; Kang CY
Blood; 2005 Jul; 106(1):201-6. PubMed ID: 15774618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
